Estadístiques de FORT-1: Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/ 3 mRNA expression
Visites totals
| views | |
|---|---|
| FORT-1: Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/ 3 mRNA expression | 58 |
Visites totals per mes
| views | |
|---|---|
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Sternberg_jco_fort.pdf(legacy) | 172 |
| Sternberg_jco_fort.pdf | 88 |
Vistes principals per país
| views | |
|---|---|
| United States | 44 |
| Australia | 4 |
| Spain | 3 |
| China | 2 |
| Netherlands | 2 |
| France | 1 |
| Israel | 1 |
| Iran | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Boardman | 9 |
| Ann Arbor | 6 |
| San Ramon | 5 |
| Fairfield | 3 |
| Mountain View | 3 |
| Ashburn | 2 |
| Barcelona | 2 |
| Menlo Park | 2 |
| Dallas | 1 |
| Dearborn | 1 |
| Fremont | 1 |
| Huétor Vega | 1 |
| Moe | 1 |
| Rochester | 1 |
| Sacramento | 1 |
| Seattle | 1 |